alpelisib,fulvestrant
novartis
['breast', 'alpelisib', 'bcsm', 'fulv']
alpelisib combined with fulvestrant represents a viable treatment option for patients with hormone receptor positive, her2-negative advanced breast cancer, regardless of mutation status. #bcsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.